Wolverine Stack Dosage & Cycle Guide

Getting the dosing right on a BPC-157 + TB-500 stack is where most researchers either succeed or waste their time. Too little of either compound and you're running a protocol that produces marginal data. Too aggressive on the front end and you're burning through material with diminishing returns.

This guide covers the dosing parameters most commonly cited in published research, how to properly reconstitute both peptides, cycle timing, and the differences between loading and maintenance phases. If you haven't read the full Wolverine Stack protocol overview, start there first for the mechanistic background.

Standard Research Dosing Parameters

Dosing for the Wolverine Stack is typically expressed in micrograms (mcg) and is based on extrapolations from published animal studies adjusted for body weight. While no standardized human clinical dosing exists for this combination, the following parameters represent the most commonly referenced ranges in the research community.

Note the different dosing units: BPC-157 is measured in micrograms while TB-500 is measured in milligrams. This reflects their different potencies and receptor binding profiles. BPC-157 is active at very small concentrations, while TB-500 requires a higher absolute dose to achieve its effects on actin regulation and cell migration.

Why the Loading Phase Matters

The loading phase serves a specific purpose: achieving tissue saturation quickly. TB-500 in particular benefits from an initial higher-dose period because its mechanism of action — promoting cell migration and angiogenesis — requires establishing a sufficient local concentration before the downstream repair processes activate.

Published equine research (TB-500 has been extensively studied in veterinary contexts) consistently shows that initial higher dosing followed by maintenance produces better outcomes than flat dosing throughout the study period. The loading phase essentially "primes" the repair environment.

BPC-157's loading phase is less critical from a mechanistic standpoint — it begins working at its standard dose — but researchers often start at the higher end of the range to establish baseline tissue protection before the more intensive repair signaling kicks in.

Reconstitution Protocol

Both BPC-157 and TB-500 are supplied as lyophilized (freeze-dried) powders that must be reconstituted with bacteriostatic water before use. This is a straightforward process, but doing it correctly is essential for maintaining peptide stability and accurate dosing.

Materials Needed

• BPC-157 vial (typically 5mg or 10mg)
• TB-500 vial (typically 5mg or 10mg)
• Bacteriostatic water (BAC water) — not sterile water, not saline
• Insulin syringes (29-31 gauge)
• Alcohol swabs

Step-by-Step Reconstitution

1. Clean the vial stoppers with alcohol swabs and let them dry completely.
2. Draw bacteriostatic water into the syringe. The amount depends on your desired concentration (see dosing math below).
3. Inject the BAC water slowly into the vial, directing the stream against the glass wall — not directly onto the powder. This prevents damage to the peptide structure.
4. Gently swirl the vial until the powder is fully dissolved. Do not shake — shaking can denature peptides.
5. Label the vial with the compound name, concentration, and reconstitution date.
6. Store in the refrigerator at 2-8°C (36-46°F). Reconstituted BPC-157 remains stable for approximately 3-4 weeks. TB-500 is slightly more stable at 4-6 weeks.

Dosing Math Made Simple

The easiest approach is to reconstitute to round numbers that make dosing calculations straightforward.

Administration Routes

How these peptides are administered matters for the research outcomes you observe. Each route has trade-offs in terms of systemic availability, localized concentration, and practical convenience.

Subcutaneous Injection (Most Common)

The standard administration route for both BPC-157 and TB-500 in research settings. Subcutaneous injections are delivered into the fat layer just beneath the skin, typically in the abdominal area, thigh, or upper arm.

• Advantages: Consistent absorption, easy to perform, well-tolerated
• BPC-157 note: Some researchers administer BPC-157 subcutaneously near the area of interest (e.g., near an injured tendon) based on the hypothesis that local concentration matters. Published data on this is mixed — BPC-157 appears to have systemic effects regardless of injection site.
• TB-500 note: TB-500 is almost exclusively administered subcutaneously. Its mechanism of action (cell migration promotion) is systemic by nature, so injection site is less relevant.

Intramuscular Injection

Less common but sometimes used for BPC-157 when targeting specific muscle tissue in research. Uses a slightly longer needle to reach the muscle layer. Generally offers faster absorption than subcutaneous but with a shorter duration of local activity.

Oral Administration (BPC-157 Only)

One of BPC-157's unique properties is its reported oral bioactivity — unusual for a peptide. This makes sense given its origin as a gastric compound. Oral BPC-157 is primarily studied for GI-related applications (gut healing, ulcer protection) rather than musculoskeletal targets.

We've covered the oral vs. injection comparison in detail in our BPC-157 analysis article.

Cycle Structure Options

The Wolverine Stack can be structured in several ways depending on research objectives. Here are the three most commonly referenced cycle frameworks.

Standard 8-Week Protocol

This is the most widely used structure and provides a good balance of data collection opportunity and compound efficiency.

Accelerated 4-Week Protocol

Used when the research timeline is compressed. Higher doses throughout, no taper. More material-intensive but produces faster observable effects.

Extended 12-Week Protocol

For longer-term research on chronic conditions or slower-healing tissue types (cartilage, chronic tendinopathy models). Uses conservative dosing to extend the observation window.

Timing and Scheduling

BPC-157 Timing

BPC-157 has a relatively short half-life of approximately 4 hours. This is why twice-daily dosing is sometimes used during loading phases — to maintain more consistent tissue levels. For single daily dosing, morning administration is most commonly reported, though there's no published data suggesting time of day significantly affects outcomes.

TB-500 Timing

TB-500 has a longer half-life and more sustained tissue activity, which is why twice-weekly dosing is sufficient. Most protocols space TB-500 doses 3-4 days apart (e.g., Monday and Thursday) for consistent coverage.

Can You Mix Them in One Injection?

This is a common question in research forums. While some researchers combine both peptides in a single syringe for convenience, others prefer separate injections to maintain precise dosing control. There's no published evidence that mixing them degrades either compound, but there's also no formal stability data on the combination in solution.

The pre-mixed BPC-157 + TB-500 blends available from some suppliers eliminate this question entirely — the compounds are co-formulated and lyophilized together.

Monitoring and Documentation

Rigorous documentation is what separates useful research from anecdotal reports. For the Wolverine Stack protocol, researchers should track:

• Dosing log: Exact amounts administered, timestamps, injection sites
• Observations: Any visible or measurable changes at defined intervals (weekly photo documentation for visible injuries, range-of-motion measurements for joint studies, etc.)
• Side effects: Any adverse reactions, injection site reactions, or unexpected observations
• Environmental variables: Storage conditions, reconstitution dates, batch numbers

For context on what outcomes to look for and expected timelines, see our Wolverine Stack results guide.

Common Mistakes to Avoid

1. Using sterile water instead of bacteriostatic water: Sterile water lacks the benzyl alcohol preservative that prevents bacterial growth. Reconstituting with sterile water means you need to use the entire vial immediately or risk contamination.
2. Shaking the vial after reconstitution: Vigorous shaking can break peptide bonds and denature the compound. Always swirl gently.
3. Storing at room temperature: Reconstituted peptides must be refrigerated. Room temperature storage degrades both BPC-157 and TB-500 rapidly.
4. Skipping the loading phase for TB-500: Going straight to maintenance dosing with TB-500 consistently produces slower and less pronounced effects in published research.
5. Inconsistent scheduling: Irregular dosing creates inconsistent tissue levels and makes it difficult to attribute any observed effects to the protocol.
6. Using low-quality peptides: Under-dosed or impure peptides are the most common reason for disappointing research outcomes. This isn't a place to cut costs.

Material Cost Estimates

For budget planning purposes, here's approximately what the standard 8-week protocol requires in terms of peptide material:

Pricing varies significantly by supplier. Budget $200-400 for an 8-week protocol using research-grade compounds from a reputable source. Cheaper options exist but typically sacrifice purity verification — see our sourcing guide for what to look for.